Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for refractory systemic juvenile idiopathic arthritis in China
ChiCTR-OPC-17011391Phase 4Completed
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA) (2 arms), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Juvenile Arthritis Disease Activity Score 27 and Inflammation index (ESR, CRP). Started Sep 2016; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on ChiCTR-OPC-17011391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011391.